Assessing Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price Swings

Simply Wall St.03-04

AdvertisementWhy Aurinia Pharmaceuticals Is On Investors’ Radar Aurinia Pharmaceuticals (AUPH) has been drawing attention after recent share price swings, with the stock now around US$14.21. You might...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616662370?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-04 06:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616662370","market":"hk","top_or_hot":-1,"title":"Assessing Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price Swings","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Aurinia Pharmaceuticals Is On Investors’ Radar Aurinia Pharmaceuticals (AUPH) has been drawing attention after recent share price swings, with the stock now around US$14.21. You might...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/assessing-aurinia-pharmaceuticals-auph-valuation-after-recen\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price Swings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price Swings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-04 06:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/assessing-aurinia-pharmaceuticals-auph-valuation-after-recen><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Aurinia Pharmaceuticals Is On Investors’ Radar Aurinia Pharmaceuticals (AUPH) has been drawing attention after recent share price swings, with the stock now around US$14.21. You might...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/assessing-aurinia-pharmaceuticals-auph-valuation-after-recen\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AUPH","symbol_name":"Aurinia Pharmaceuticals Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/assessing-aurinia-pharmaceuticals-auph-valuation-after-recen","article_id":"2616662370","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/assessing-aurinia-pharmaceuticals-auph-valuation-after-recen","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616662370","pubTimestamp":1772576631,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Aurinia Pharmaceuticals Is On Investors’ Radar\nAurinia Pharmaceuticals (AUPH) has been drawing attention after recent share price swings, with the stock now around US$14.21. You might be asking whether the current level still reflects the company’s fundamentals.\nSee our latest analysis for Aurinia Pharmaceuticals.\nRecent trading has been choppy, with a 1-day share price return of 0.28% contrasting with a 90-day share price return decline of 10.69%. However, the 1-year total shareholder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"AUPH":"Aurinia Pharmaceuticals Inc","BK4139":"生物科技"},"translate_title":"在近期股价波动后评估Aurinia Pharmaceuticals(AUPH)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUPH":1.5},"content_text":"AdvertisementWhy Aurinia Pharmaceuticals Is On Investors’ Radar Aurinia Pharmaceuticals (AUPH) has been drawing attention after recent share price swings, with the stock now around US$14.21. You might be asking whether the current level still reflects the company’s fundamentals. See our latest analysis for Aurinia Pharmaceuticals. Recent trading has been choppy, with a 1-day share price return of 0.28% contrasting with a 90-day share price return decline of 10.69%. However, the 1-year total shareholder return of 78.07% and 3-year total shareholder return of 54.96% indicate that investors who stayed invested saw stronger overall outcomes than the shorter term moves suggest. If Aurinia’s swings have you thinking about where else growth stories might emerge in healthcare, it could be a good moment to scan our list of 28 healthcare AI stocks as another way to spot potential opportunities. With Aurinia trading at US$14.21, an intrinsic discount estimate of about 63% and a price target of US$17 in the background, the key question is whether this represents a buying opportunity or if markets already reflect expectations for future growth. Most Popular Narrative: 14.7% Undervalued With Aurinia’s fair value estimate sitting at about $16.67 against a last close of $14.21, the leading narrative suggests the current price leaves a margin between market expectations and modeled fundamentals.  A biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. What are the underlying business or industry changes driving this perspective?  Read the complete narrative. Curious what justifies that fair value gap? The most followed view leans on steady top line expansion, firmer margins, and a lower earnings multiple than many peers. The key point is how those three factors are projected to work together over the next few years. Result: Fair Value of $16.67 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges heavily on LUPKYNIS, so any competitive or patent setbacks, or higher than expected R&D spending, could quickly weaken that underpriced story. Find out about the key risks to this Aurinia Pharmaceuticals narrative. Next Steps Given the mixed feel of this story, with both concerns and reasons for optimism in play, it makes sense to look at the numbers yourself and move quickly to shape your own view. A good place to start is the 4 key rewards and 2 important warning signs that other investors are watching closely. Looking for more investment ideas? If Aurinia has caught your attention, do not stop here. A few minutes with focused stock lists can surface opportunities you might regret overlooking later.  Target resilient upside by checking out 45 high quality undervalued stocks that may combine stronger fundamentals with prices that still sit below their estimated worth. Prioritise staying power by scanning solid balance sheet and fundamentals stocks screener (41 results) where companies pair healthier finances with business models that can better handle shocks. Hunt for tomorrow’s potential standouts early through our screener containing 24 high quality undiscovered gems before they attract wider market attention.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616662370","isCrawlerRequest":true}